Journals / Kadın Doğum Dergisi / 2004 / Cilt: 3 - Sayı: 2

Lipid profile in patients with polycystic ovary syndrome

Polikistik over sendromlu olgularda lipid profili

Pages
448–451
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We believe hyperandrogenism, encountered in patients with polycystic ovarian syndrome, negatively impacts lipid metabolism regardless of the body mass index and body fat distribution.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: In this study we aimed to study lipid profile in patients with polycystic ovarian syndrome (PCOS).
📊
Key Findings & Data:Material and Method: This was a case control study done in a single center between the dates October 2003 and March 2004.
💡
Conclusion & Impact:We believe hyperandrogenism, encountered in patients with polycystic ovarian syndrome, negatively impacts lipid metabolism regardless of the body mass index and body fat distribution.
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: In this study we aimed to study lipid profile in patients with polycystic ovarian syndrome (PCOS). Material and Method: This was a case control study done in a single center between the dates October 2003 and March 2004. Eighteen women who presented with infertility and diagnosed with PCOS were included in this study as the study group, and ten women with infertility due to male factor and without any medical problems were included as the control group. Samples were drawn from all the cases on the third day of the menstrual cycle after an overnight fasting for lipid and hormone profile analysis. Student's t test and Mann-Whitney U test were used for statistical analysis. Results: Both groups were similar in age, body mass index and waist/hip ratio parameters. Luteinizing hormone (LH), total testosterone, androstenedione levels and Ferriman-Gallwey hirsutism score were significantly higher in the PCOS group. Estradiol and dihydroepiandrosterone sulphate (DHEA-S), LDL and total cholesterol levels were similar in each group. Triglyceride levels were higher in the PCOS group when compared with the control group (114.2±38.8 mg/dL , 81.Ü29.1 mg/dL respectively; p=0.049), whereas HDL levels were lower in the PCOS group (48.0±5.9mg/dL, 66.2±12.3 mg/dL respectively; p=0.001). VLDL levels in the PCOS group were significantly higher than the control group (22.8±7.8 mg/dL, 16.2±5.8 mg/dL; p=0.049 respectively). Conclusion: There is a strong correlation between dyslipidemia and cardiovascular disease in the long term. We believe hyperandrogenism, encountered in patients with polycystic ovarian syndrome, negatively impacts lipid metabolism regardless of the body mass index and body fat distribution.

Özet

Amaç: Polikistikoversendromlu(PKOS) olgularda lipid profilinin değerlendirilmesi. Materyal ve Mctod: Tek merkezli, vaka kontrol niteliğindeki çalışmamıza, Kasım 2003-Mart 2004 tarihleri arasında, infertilite yakınması olan ve PKOS tanısı alan 18 kadın ile (çalışma grubu) erkek faktör infertilitesi olan ve herhangi bir medikal problemi olmayan 10 kadın (kontrol grubu) dahil edildi. Tüm olgularda menstruasyonun 3. günü, bir gecelik açlığı takiben hormon ve lipid profili değerlendirildi. Bulgular Student's t test ve Mann-Whitney U test ile değerlendirildi. Bulgular: Her iki grup; yaş, vücut kitle indeksi ve bel/kalça oranı açısından benzerdi. LH, total testosteron, androstenedione düzeyleri ve Ferriman-Gallwey hirşutismus skoru PKOS grubunda anlamlı oranda yüksekti. Estradiol, DHEA-S, total kolesterol (TC) ve düşük dansiteli lipoprotein (LDL-C) seviyeleri her iki grupta benzerdi. Ortalama trigliserid (TG) düzeyi PKOS grubunda anlamlı oranda yüksek olarak saptanırken (sırası ile; 114.2±38,8 mg/dL, 81.1±29.1 mg/dL; p= 0.049), yüksek dansiteli lipoprotein (HDL-C) düzeyi PKOS grubunda anlamlı oranda düşük olarak saptandı (sırası ile; 48.0±5.9mg/dL, 66.2±12.3 mg/dL; p=0.001). Çok düşük dansiteli lipoprotein (VLDL-C) düzeyi PKOS grubunda kontrol grubuna oranla anlamlı oranda yüksek saptandı (sırası ile; 22.8±7.8 mg/dL, 16.2±5.8 mg/dL; p=0.049). Sonuç: Dislipidemi uzun dönemde gelişebilecek olan kardiyovasküler hastalık riskinde artış ile beraberdir. PKOS'lu kadınlarda hiperandrojenizm vücut kitle indeksi ve vücut yağ dağılımından bağımsız olarak lipid metabolizmasını kötü yönde etkileyen bir faktördür.

🔖

Cite This Article

SÖNMEZER, M., AYTAÇ, R., ERGÜN, A., ÜSTÜNER, I., GÜLLÜ, S. (2022). Lipid profile in patients with polycystic ovary syndrome. Kadın Doğum Dergisi, Cilt: 3 - Sayı: 2, 448–451. https://ajindex.com/articles/569092

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 3: 853-61.
  2. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.
  3. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction.Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604.
  4. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981;141:1128-31. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
  5. Ferriman, D. and Gallwey, J.D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21:11408. Slowinska-Srzednicka J, Zgliczynski S, Wierzbicki M, Srzednicki M, Stopinska-Gluszak U, Zgliczynski W, Soszynski P,Chotkowska E, Bednarska M, Sadowski Z. The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. J Endocrinol Invest 1991; 14:569-75.
  6. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Küller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995; 15:821-6.
  7. Velazquez M E, Bellabarba GA, Mendoza S, Sanchez L. Postprandial triglyceride response in patients with polycystic ovary syndrome: relationship with waist-to-hip ratio and insulin. Fertil Steril 2000;74:1159-63.
  8. Wild RA, Applebaum-Bowden D, Demers LM, Bartholomew M, Landis JR, Hazzard WR, Santen RJ. Lipoprotein lipids in women with androgen excess: independent associations with increased insulin and androgen. Clin Chem 1990;36:283-9.
  9. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors ofdyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607-13.
  10. Erel CT, Senturk LM, Kaleli S, Gezer A, Baysal B, Tasan E. Is serum leptin level regulated by thyroid functions, lipid metabolism and insulin resistance in polycystic ovary syndrome? Gyne